Stricter Rules for GLP-1 Drug Ads

The Indian government, through the Drugs Controller General of India (DCGI), has imposed a strict ban on all forms of advertising for Glucagon-Like Peptide-1 (GLP-1) receptor agonists. DCGI Rajeev Singh Raghuvanshi signed this directive, which targets direct and indirect promotions across all media. The aim is to curb drug misuse by consumers and prevent exaggerated claims, especially concerning weight loss. The advisory clearly states that "advertisement including surrogate advertisement of the said product shall be strictly prohibited."

This action comes at a crucial time, as patents for key GLP-1 drugs, like Novo Nordisk's semaglutide (Ozempic, Wegovy), are set to expire in India by March 2026.

India's Booming GLP-1 Market

India's GLP-1 receptor agonist market is growing rapidly. It is projected to increase nearly fivefold, from about INR 1,000–1,200 crore in 2025 to INR 4,500–5,000 crore by 2030. The market was valued at $115 million in 2024 and is expected to reach $578.9 million by 2030, fueled by high rates of type 2 diabetes and obesity.

The upcoming patent expiration for semaglutide is expected to lead to a significant number of generic versions, with drug prices potentially falling by 40-50% in FY27. This regulatory ban comes before this market shift, suggesting an effort to control advertising excesses before generic competition heats up.

Global Players and Valuation Differences

Global giants Novo Nordisk and Eli Lilly dominate the GLP-1 segment. Novo Nordisk, with its semaglutide products (Ozempic, Wegovy), has seen substantial sales, but its growth has slowed amid increasing competition. The company's market capitalization is around $171 billion, with a P/E ratio of approximately 10.78-11.41.

In contrast, Eli Lilly's drugs using tirzepatide (Mounjaro, Zepbound) have shown remarkable sales growth, pushing its market value to over $960 billion and a P/E ratio of about 44.35-44.65. Lilly's fast revenue growth from Zepbound and Mounjaro has outpaced Novo Nordisk in US GLP-1 prescriptions.

The advertising ban in India could affect marketing strategies for all companies, potentially making the promotional playing field more even as patents expire.

Marketing Challenges and Regulatory Scrutiny

The ban on advertising creates significant challenges for operations and marketing. Pharmaceutical companies will need to change their plans to follow the DCGI's directive, which covers all direct or indirect promotional activities.

This move highlights increased regulatory attention on GLP-1 drugs, driven by concerns over off-label use, potential side effects, and the rise of unapproved or counterfeit products, as noted by WHO alerts. The Indian market, though large, is very sensitive to price.

The expected price drops after patent expiry could lead to intense competition and lower profits. Furthermore, the uncontrolled availability of these drugs in some areas before this ban points to an ongoing problem in ensuring responsible selling and patient safety. The DCGI's stance shows a commitment to preventing misleading marketing that overstates benefits or downplays lifestyle changes – a critical issue given the substantial rise in obesity and diabetes in India. The market is now facing fragmentation as many Indian companies prepare to launch generics.

Navigating Future Demand and Rules

In the near future, pharmaceutical firms operating in India will focus more on compliance. The market will likely deal with the dual pressures of stricter rules and aggressive competition from generics after the semaglutide patent expires.

Analysts expect demand for GLP-1 therapies to remain strong, driven by the continuing increase in metabolic disorders. However, the regulatory environment is likely to keep changing, with the possibility of more guidance on approved uses and marketing practices.

Companies that can navigate these complex rules while clearly showing the medical benefits of their products, whether branded or generic, will be best positioned. Successfully integrating risk management plans and adhering to ethical advertising standards will be key to maintaining trust and market access.